Rejuva
Rejuva is a gene therapy which is under development for the treatment of obesity and diabetes.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Rejuva is a gene therapy which is under development for the treatment of obesity and diabetes. It is an adeno-associated virus (AAV)-based gene therapy which involves an engineered variant of human insulin promotor and which aims to permanently increase nutrient-responsive secretion glucagon-like peptide-1 (GLP-1) by pancreatic β-cells.
The therapy is administered via a 25-gauge needle delivery system guided by endoscopic ultrasound in a one-time outpatient treatment. It is intended as a permanent alternative to GLP-1 agonists like semaglutide. Rejuva is under development by Fractyl Health and is in the preclinical research stage of development.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1334821195 under CC BY-SA 4.0; modifications have been made.